Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 5/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | CYP1A1 | P04798 | 1/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | CYP1B1 | Q16678 | 1/20 | 0.46 |
| ▸ | CHEK1 | O14757 | 2/20 | 0.43 |
| ▸ | NPC1 | O15118 | 3/20 | 0.40 |
| ▸ | PDPK1 | O15530 | 2/20 | 0.40 |
| ▸ | POLB | P06746 | 2/20 | 0.40 |
| ▸ | MAPT | P10636 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | IKBKB | O14920 | 2/20 | 0.38 |
| ▸ | CHUK | O15111 | 1/20 | 0.38 |
| ▸ | MCHR1 | Q99705 | 3/20 | 0.36 |
| ▸ | PRKDC | P78527 | 1/20 | 0.36 |
| ▸ | AHR | P35869 | 2/20 | 0.36 |
| ▸ | CMA1 | P23946 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL391808 | 0.84 | PDPK1 (0.57) | RAB9ASMN1; SMN2KDM4ECYP1A2NPC1 | |
| SCHEMBL390356 | 0.82 | PDPK1 (0.42) | RAB9ASMN1; SMN2KDM4ELMNACYP1A2 | |
| SCHEMBL390245 | 0.77 | HDAC6 (0.46) | RAB9ASMN1; SMN2KDM4ECHEK1NPC1 | |
| SCHEMBL392148 | 0.76 | ROCK1 (0.47) | RAB9ASMN1; SMN2KDM4ENPC1PDPK1 | |
| SCHEMBL1144530 | 0.76 | RAB9A (0.50) | RAB9ASMN1; SMN2KDM4ELMNACYP1A1 | |
| SCHEMBL390192 | 0.76 | KDM4E (0.47) | RAB9ASMN1; SMN2KDM4ELMNANPC1 | |
| SCHEMBL21963465 | 0.75 | RAB9A (0.40) | RAB9ASMN1; SMN2KDM4ELMNACYP1A1 | |
| SCHEMBL4208111 | 0.73 | RAB9A (0.74) | RAB9ASMN1; SMN2KDM4ELMNANPC1 | |
| SCHEMBL389801 | 0.73 | STK17B (0.43) | RAB9ASMN1; SMN2KDM4ELMNANPC1 | |
| SCHEMBL2582411 | 0.71 | ALDH1A1 (0.44) | RAB9ASMN1; SMN2KDM4ELMNANPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120302547-A1 | NOVEL MCH RECEPTOR ANTAGONISTS | ELI LILLY AND COMPANY (US) | 2012-11-29 | — | — | US | disclosed |
| US-20120302547-A1 | NOVEL MCH RECEPTOR ANTAGONISTS | ELI LILLY AND COMPANY (US) | 2012-11-29 | — | — | US | disclosed |
| US-20120302547-A1 | NOVEL MCH RECEPTOR ANTAGONISTS | ELI LILLY AND COMPANY (US) | 2012-11-29 | — | — | US | disclosed |
| US-8263772-B2 | MCH receptor antagonists | ELI LILLY AND COMPANY (US) | 2012-09-11 | — | — | US | disclosed |
| US-8263772-B2 | MCH receptor antagonists | ELI LILLY AND COMPANY (US) | 2012-09-11 | — | — | US | disclosed |
| US-8263772-B2 | MCH receptor antagonists | ELI LILLY AND COMPANY (US) | 2012-09-11 | — | — | US | disclosed |
| US-8101764-B2 | MCH receptor antagonists | ELI LILLY AND COMPANY (US) | 2012-01-24 | — | — | US | disclosed |
| US-20100016350-A1 | NOVEL MCH RECEPTOR ANTAGONISTS | ELI LILLY AND COMPANY | 2010-01-21 | — | — | US | disclosed |
| CN-101460503-A | Novel MCH receptor antagonists | LILLY CO ELI (US) | 2009-06-17 | — | — | CN | disclosed |
| CN-101454328-A | Novel mch receptor antagonists | LILLY CO ELI (US) | 2009-06-10 | — | — | CN | disclosed |
| US-20090093456-A1 | NOVEL MCH RECEPTOR ANTAGONISTS | ELI LILLY AND COMPANY | 2009-04-09 | — | — | US | disclosed |
| US-20090093456-A1 | NOVEL MCH RECEPTOR ANTAGONISTS | ELI LILLY AND COMPANY | 2009-04-09 | — | — | US | disclosed |
| US-20090093456-A1 | NOVEL MCH RECEPTOR ANTAGONISTS | ELI LILLY AND COMPANY | 2009-04-09 | — | — | US | disclosed |
| EP-2029610-A2 | NOVEL MCH RECEPTOR ANTAGONISTS | Eli Lilly & Company (US) | 2009-03-04 | — | — | EP | disclosed |
| EP-2029609-A2 | NOVEL MCH RECEPTOR ANTAGONISTS | Eli Lilly & Company (US) | 2009-03-04 | — | — | EP | disclosed |
| WO-2007146758-A2 | NOVEL MCH RECEPTOR ANTAGONISTS | ELI LILLY AND COMPANY (US) | 2007-12-21 | — | — | WO | disclosed |
| WO-2007146758-A2 | NOVEL MCH RECEPTOR ANTAGONISTS | ELI LILLY AND COMPANY (US) | 2007-12-21 | — | — | WO | disclosed |
| WO-2007146759-A2 | NOVEL MCH RECEPTOR ANTAGONISTS | ELI LILLY AND COMPANY (US) | 2007-12-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100016350-A1 | NOVEL MCH RECEPTOR ANTAGONISTS | MCHR1, MCHR2, MC1R | RAB9A 602/4885SMN1; SMN2 2533/4885KDM4E 2661/4885 |
| US-20120302547-A1 | NOVEL MCH RECEPTOR ANTAGONISTS | MCHR1, MCHR2, MC1R | RAB9A 553/4885SMN1; SMN2 2564/4885KDM4E 2644/4885 |
| US-20090093456-A1 | NOVEL MCH RECEPTOR ANTAGONISTS | MCHR1, MCHR2, MC1R | RAB9A 600/4885SMN1; SMN2 2550/4885KDM4E 2628/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.